Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 1, 2024
Reporting Period: Second quarter ended June 30, 2024
This filing serves as a notification that the company announced its financial results for the second quarter of 2024. The detailed financial data is contained within the attached press release (Exhibit 99.1) and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial figures. The following metrics are not present in the source text:
- Revenue
- Profit (Net Income/Loss)
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: Specific values for these metrics are not available in the provided filing text.
Material Changes
The filing text does not provide specific data regarding material changes in financial performance compared to the prior comparable period. It only confirms the announcement of the Q2 2024 results.
Guidance, Outlook, and Risks
The provided text does not include management commentary, forward-looking guidance, specific risk factors, contingencies, or unusual items. These details are referenced as being contained in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 1, 2024) for actual revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for updated financial guidance or outlook statements in the full press release.
- Confirm the status of the company's cash position and debt obligations as detailed in the full financial report.